Terms ending in 2032
Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,045,557 | NEIL3 Peptides and Vaccines Including the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,725,490 | ERAP1-DERIVED Peptide and Use Thereof In force · High confidence | The University of Tokushima and Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,073,021 | Device and Method for Automatically Preparing Emulsion Drug In force · High confidence | Oncotherapy Science, Inc. and The University of Tokyo | In force | High confidence | |
| US 9,849,166 | Topk Peptides and Vaccines Including the Same In force · High confidence | OncoTherapy Science, Inc. | In force | High confidence | |
| US 9,119,800 | HIG2 and URLC10 Epitope Peptide and Vaccines Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 8,962,648 | Tricyclic Compounds and PBK Inhibitors Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,427,461 | Topk Peptides and Vaccines Including the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,067,937 | 1,5-Naphthyridine Derivatives and Melk Inhibitors Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,345,709 | 1,5-Naphthyridine Derivatives and Melk Inhibitors Containing the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.